{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:09:33Z","timestamp":1793045373630,"version":"4.5.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2015,4,30]],"date-time":"2015-04-30T00:00:00Z","timestamp":1430352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0125603","type":"journal-article","created":{"date-parts":[[2015,4,30]],"date-time":"2015-04-30T20:28:28Z","timestamp":1430425708000},"page":"e0125603","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":57,"title":["Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats"],"prefix":"10.1371","volume":"10","author":[{"given":"Sarika","family":"Kapoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meliana","family":"Riwanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilka","family":"Edenhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Segerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharyn","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf P.","family":"W\u00fcthrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,4,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","article-title":"Polycystic kidney disease","volume":"60","author":"PC Harris","year":"2009","journal-title":"Annu Rev Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"VE Torres","year":"2007","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1523-1755.2003.00776.x","article-title":"Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease","volume":"63","author":"RW Schrier","year":"2003","journal-title":"Kidney Int"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/14656566.2014.903923","article-title":"Pharmacological management of polycystic kidney disease","volume":"15","author":"RP W\u00fcthrich","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MNH.0b013e3283621510","article-title":"Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease","volume":"22","author":"O Devuyst","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"VE Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","article-title":"Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug","volume":"26","author":"E Meijer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"VH Gattone 2nd","year":"2003","journal-title":"Nat Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"VE Torres","year":"2004","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"X Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"F261","DOI":"10.1152\/ajprenal.00345.2014","article-title":"Effects of hydration in rats and mice with polycystic kidney disease","volume":"308","author":"K Hopp","year":"2015","journal-title":"American Journal of Physiology\u2014Renal Physiology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"VE Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"X Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","article-title":"Increased water intake decreases progression of polycystic kidney disease in the PCK rat","volume":"17","author":"S Nagao","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ki.2012.225","article-title":"Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation","volume":"82","author":"TA Ho","year":"2012","journal-title":"Kidney Int"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2215\/CJN.00790209","article-title":"A case for water in the treatment of polycystic kidney disease","volume":"4","author":"VE Torres","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2215\/CJN.03950510","article-title":"Water prescription in autosomal dominant polycystic kidney disease: a pilot study","volume":"6","author":"CJ Wang","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.199","article-title":"Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats","volume":"84","author":"X Wang","year":"2013","journal-title":"Kidney Int"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrneph.2010.38","article-title":"Renal glucose transporters: novel targets for hyperglycemia management","volume":"6","author":"A Mather","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1681\/ASN.V561349","article-title":"Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease","volume":"5","author":"AB Chapman","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00125-014-3396-4","article-title":"Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration","volume":"57","author":"M Skrtic","year":"2014","journal-title":"Diabetologia"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.ajkd.2014.02.010","article-title":"Sodium\/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes","volume":"64","author":"L De Nicola","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/oby.2012.59","article-title":"Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats","volume":"20","author":"JJ Devenny","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat","volume":"302","author":"SC Thomson","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm701272q","article-title":"Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"51","author":"W Meng","year":"2008","journal-title":"J Med Chem"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","volume":"57","author":"S Han","year":"2008","journal-title":"Diabetes"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/dmd.109.029165","article-title":"In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans","volume":"38","author":"M Obermeier","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1681\/ASN.2005060601","article-title":"Missense mutation in sterile alpha motif of novel protein SamCystin is associated with polycystic kidney disease in Cy\/+ rat","volume":"16","author":"JH Brown","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/ng.2681","article-title":"ANKS6 is a central component of a nephronophthisis module linking NEK8 to INVS and NPHP3","volume":"45","author":"S Hoff","year":"2013","journal-title":"Nat Genet"},{"key":"ref30","first-page":"585","article-title":"Pathophysiology of obstructive nephropathy in the newborn","volume":"18","author":"RL Chevalier","year":"1998","journal-title":"Semin Nephrol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1093\/ndt\/gfr744","article-title":"The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease","volume":"27","author":"B Reed","year":"2012","journal-title":"Nephrol Dial Transplant"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0125603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T21:26:57Z","timestamp":1651872417000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0125603"}},"subtitle":[],"editor":[{"given":"Eric","family":"Feraille","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,4,30]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0125603","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,30]]}}}